Southern West Virginia News

WASHINGTON, D.C. - Congresswoman Carol Miller (R-WV) reintroduced the Manufacturing API, Drugs, and Excipients (MADE) in America Act to prevent U.S. pharmaceutical supply chain dependence on China and other foreign adversaries. The MADE in America Act will stimulate domestic manufacturing of drugs and pharmaceutical supplies such as active pharmaceutical ingredients (API) and personal protective equipment (PPE) while reducing drug shortages. 

“The success of United States supply chain can be our best asset in deterring China and other adversaries," said Congresswoman Miller. "Fixing the vulnerabilities in our supply chain bolsters domestic pharmaceutical manufacturing, enhances our national security, and lowers costs for Americans. The MADE in America Act is necessary to keep our medical supply chain competitive and promote job creation in the United States.”

"With China spying on Americans, threatening an invasion of Taiwan, and ignoring human rights, it is clear America cannot continue to rely on them for lifesaving medications," said Congressman Carter. "This legislation is designed to significantly reduce the advantage that foreign adversaries provide and encourage companies to maintain, expand or relocate their production activities back to the United States and its territories through a tax credit that will serve the most disadvantaged communities in our nation. We simply can no longer be dependent on our enemies for anything, especially essential medications and medical supplies. America must secure pharmaceutical independence."

Joining Representative Miller in the reintroduction of the MADE in America Act are Representatives Earl L. “Buddy” Carter (R-GA), Darren Soto (D-FL), Matt Cartwright (D-PA), Richard Hudson (R-NC), Gus Bilirakis (R-FL), Morgan Griffith (R-VA), Jeff Van Drew (R-NJ), Troy Balderson (R-OH), Rick Crawford (R-AR), Diana Harshbarger (R-TN), and Nick Langworthy (R-NY).

Original source can be found here.